Beleave Inc. (CNSX:BE) is pleased to announce that it has successfully completed a Natural Sciences and Engineering Research Council (NSERC) Engage funded research project in collaboration with lead investigator Dr. Lesley Campbell, associate professor in the Ryerson University Department of Chemistry and Biology. In this work, Beleave and the Campbell lab have worked on optimizing methods for cannabinoid/terpene extraction, and compared the efficiency of this method with the efficiency of extraction of a panel of other practical extraction methods reported in the literature and used in industrial cannabis oil production. The results of the project have led to the identification of a unique approach for cannabinoid extraction and recovery. Beleave plans to support project collaborators in preparing a manuscript for publication in the International Journal of Analytical Science.
“This represents an exciting addition to Beleave’s IP portfolio, and creates opportunity for future cannabis product development and commercialization. The development of such technologies is consistent with Beleave’s corporate mission of being a leading provider of medical cannabis products in Canada”, commented Beleave CEO, Roger Ferreira.
“I find this research contribution exciting — it is imperative that knowledge-generating public institutions, like universities, get involved in developing high-quality, pharmaceutical extraction processes for patients, and support a healthy business environment where established and emerging companies all have access to cost-efficient, consistent and safe processes”, remarked Ryerson researcher, Lesley Campbell.
Beleave, Inc. is a biotech company committed to becoming a licensed producer under the Access to Cannabis for Medical Purposes Regulations (the “ACMPR“). Beleave’s wholly-owned subsidiary First Access Medical Inc. (“FAM“) has applied for a license to cultivate and sell medical marihuana pursuant to the ACMPR. As of the date hereof, FAM has successfully advanced past the review stage, and has been issued an affirmation letter from Health Canada prior to a request for a pre-licensing inspection. Beleave’s purpose-built facility is located near Hamilton, Ontario.
Ryerson University is Canada’s leader in innovative, career-oriented education. Urban, culturally diverse and inclusive, the university is home to more than 41,500 students, including 2,400 master’s and PhD students, 3,200 faculty and staff, and nearly 170,000 alumni worldwide. For more information, visit www.ryerson.ca
NSERC invests over $1 billion each year in natural sciences and engineering research in Canada. Our investments deliver discoveries – valuable world-firsts in knowledge claimed by a brain trust of over 11,000 professors. Our investments enable partnerships and collaborations that connect industry with discoveries and the people behind them. Researcher-industry partnerships established by NSERC help inform R&D, solve scale-up challenges, and reduce the risks of developing high-potential technology.
NSERC also provides scholarships and hands-on training experience for more than 30,000 post-secondary students and post-doctoral fellows. These young researchers will be the next generation of science and engineering leaders in Canada.
This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the completion of the ACMPR licensing process, meeting the requirements of the ACMPR, and the start of production. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com.